AAPL295.18+5.82 (+2.01%) ▲|ABBV249.56-2.08 (-0.83%) ▼|ABT92.85+2.11 (+2.33%) ▲|ACN131.13+6.69 (+5.38%) ▲|ADBE212.61+7.59 (+3.70%) ▲|AMAT663.31-59.69 (-8.26%) ▼|AMD551.15-29.77 (-5.12%) ▼|AMGN360.80-1.32 (-0.36%) ▼|AMT165.55+1.98 (+1.21%) ▲|AMZN241.81+3.47 (+1.46%) ▲|AVGO370.59-7.16 (-1.90%) ▼|AXP348.72+10.47 (+3.10%) ▲|BA217.87+1.40 (+0.65%) ▲|BAC58.23+1.25 (+2.19%) ▲|BKNG184.71+6.47 (+3.63%) ▲|BLK978.17+16.61 (+1.73%) ▲|BMY56.66-0.97 (-1.67%) ▼|BNY146.74+2.13 (+1.47%) ▲|BRK-B503.15+2.76 (+0.55%) ▲|C140.73+0.77 (+0.55%) ▲|CAT1,019.34-45.56 (-4.28%) ▼|CL92.49+0.81 (+0.88%) ▲|CMCSA24.16-0.39 (-1.59%) ▼|COF204.94+4.32 (+2.15%) ▲|COP103.74-0.22 (-0.21%) ▼|COST926.70-8.77 (-0.94%) ▼|CRM164.94+8.28 (+5.28%) ▲|CSCO116.33-1.13 (-0.96%) ▼|CVS104.11+0.66 (+0.63%) ▲|CVX166.32+0.56 (+0.34%) ▲|DE631.49-2.84 (-0.45%) ▼|DHR194.76+4.28 (+2.24%) ▲|DIS97.04+0.79 (+0.82%) ▲|DUK126.18-0.40 (-0.32%) ▼|EMR142.47-0.68 (-0.48%) ▼|FDX315.03+1.90 (+0.61%) ▲|GD364.11+9.87 (+2.79%) ▲|GE375.80+2.07 (+0.55%) ▲|GEV1,153.80-21.06 (-1.79%) ▼|GILD126.20-0.15 (-0.11%) ▼|GM76.53-0.56 (-0.72%) ▼|GOOG356.33+3.00 (+0.85%) ▲|GOOGL359.45+2.08 (+0.58%) ▲|GS1,024.23+12.86 (+1.27%) ▲|HD356.34+3.66 (+1.04%) ▲|HON224.19+0.29 (+0.13%) ▲|IBM293.10+11.89 (+4.23%) ▲|INTC129.30-10.33 (-7.40%) ▼|INTU272.00+11.00 (+4.21%) ▲|ISRG404.99+7.31 (+1.84%) ▲|JNJ252.34-1.63 (-0.64%) ▼|JPM334.34+7.01 (+2.14%) ▲|KO81.76+0.49 (+0.60%) ▲|LIN536.04+17.10 (+3.30%) ▲|LLY1,191.20-8.24 (-0.69%) ▼|LMT521.48+12.02 (+2.36%) ▲|LOW225.28+4.79 (+2.17%) ▲|LRCX396.34-36.99 (-8.54%) ▼|MA528.55+14.95 (+2.91%) ▲|MCD270.44+0.13 (+0.05%) ▲|MDLZ59.17+1.33 (+2.29%) ▲|MDT79.40+1.17 (+1.50%) ▲|META618.43+55.14 (+9.79%) ▲|MMM161.68-0.23 (-0.14%) ▼|MO71.96+0.01 (+0.01%) ▲|MRK126.59-1.91 (-1.49%) ▼|MS211.51+2.47 (+1.18%) ▲|MSFT384.67+11.65 (+3.12%) ▲|MU1,053.73-100.57 (-8.71%) ▼|NEE86.95-0.82 (-0.93%) ▼|NFLX73.39+1.99 (+2.78%) ▲|NKE43.06+2.01 (+4.90%) ▲|NOW105.65+6.37 (+6.42%) ▲|NVDA196.89-3.20 (-1.60%) ▼|ORCL145.11-1.44 (-0.98%) ▼|PEP140.05+4.65 (+3.43%) ▲|PFE23.94-0.15 (-0.60%) ▼|PG146.37-0.27 (-0.18%) ▼|PLTR127.19+10.52 (+9.02%) ▲|PM178.43-2.48 (-1.37%) ▼|QCOM185.52+0.73 (+0.39%) ▲|RTX191.39+1.66 (+0.87%) ▲|SBUX101.57-0.63 (-0.61%) ▼|SCHW94.40+2.13 (+2.31%) ▲|SO95.79+0.08 (+0.08%) ▲|SPG221.82-1.84 (-0.82%) ▼|T20.64-0.06 (-0.29%) ▼|TMO520.60+19.24 (+3.84%) ▲|TMUS172.53+4.80 (+2.86%) ▲|TSLA429.34+8.74 (+2.08%) ▲|TXN299.13+1.06 (+0.36%) ▲|UBER73.35+1.19 (+1.65%) ▲|UNH421.65+6.02 (+1.45%) ▲|UNP276.15+4.15 (+1.53%) ▲|UPS109.83+2.33 (+2.17%) ▲|USB61.98+1.58 (+2.62%) ▲|V352.39+9.30 (+2.71%) ▲|VZ42.08-0.27 (-0.63%) ▼|WFC85.52+2.88 (+3.49%) ▲|WMT108.05-5.21 (-4.60%) ▼|XOM136.85+0.13 (+0.10%) ▲|AAPL295.18+5.82 (+2.01%) ▲|ABBV249.56-2.08 (-0.83%) ▼|ABT92.85+2.11 (+2.33%) ▲|ACN131.13+6.69 (+5.38%) ▲|ADBE212.61+7.59 (+3.70%) ▲|AMAT663.31-59.69 (-8.26%) ▼|AMD551.15-29.77 (-5.12%) ▼|AMGN360.80-1.32 (-0.36%) ▼|AMT165.55+1.98 (+1.21%) ▲|AMZN241.81+3.47 (+1.46%) ▲|AVGO370.59-7.16 (-1.90%) ▼|AXP348.72+10.47 (+3.10%) ▲|BA217.87+1.40 (+0.65%) ▲|BAC58.23+1.25 (+2.19%) ▲|BKNG184.71+6.47 (+3.63%) ▲|BLK978.17+16.61 (+1.73%) ▲|BMY56.66-0.97 (-1.67%) ▼|BNY146.74+2.13 (+1.47%) ▲|BRK-B503.15+2.76 (+0.55%) ▲|C140.73+0.77 (+0.55%) ▲|CAT1,019.34-45.56 (-4.28%) ▼|CL92.49+0.81 (+0.88%) ▲|CMCSA24.16-0.39 (-1.59%) ▼|COF204.94+4.32 (+2.15%) ▲|COP103.74-0.22 (-0.21%) ▼|COST926.70-8.77 (-0.94%) ▼|CRM164.94+8.28 (+5.28%) ▲|CSCO116.33-1.13 (-0.96%) ▼|CVS104.11+0.66 (+0.63%) ▲|CVX166.32+0.56 (+0.34%) ▲|DE631.49-2.84 (-0.45%) ▼|DHR194.76+4.28 (+2.24%) ▲|DIS97.04+0.79 (+0.82%) ▲|DUK126.18-0.40 (-0.32%) ▼|EMR142.47-0.68 (-0.48%) ▼|FDX315.03+1.90 (+0.61%) ▲|GD364.11+9.87 (+2.79%) ▲|GE375.80+2.07 (+0.55%) ▲|GEV1,153.80-21.06 (-1.79%) ▼|GILD126.20-0.15 (-0.11%) ▼|GM76.53-0.56 (-0.72%) ▼|GOOG356.33+3.00 (+0.85%) ▲|GOOGL359.45+2.08 (+0.58%) ▲|GS1,024.23+12.86 (+1.27%) ▲|HD356.34+3.66 (+1.04%) ▲|HON224.19+0.29 (+0.13%) ▲|IBM293.10+11.89 (+4.23%) ▲|INTC129.30-10.33 (-7.40%) ▼|INTU272.00+11.00 (+4.21%) ▲|ISRG404.99+7.31 (+1.84%) ▲|JNJ252.34-1.63 (-0.64%) ▼|JPM334.34+7.01 (+2.14%) ▲|KO81.76+0.49 (+0.60%) ▲|LIN536.04+17.10 (+3.30%) ▲|LLY1,191.20-8.24 (-0.69%) ▼|LMT521.48+12.02 (+2.36%) ▲|LOW225.28+4.79 (+2.17%) ▲|LRCX396.34-36.99 (-8.54%) ▼|MA528.55+14.95 (+2.91%) ▲|MCD270.44+0.13 (+0.05%) ▲|MDLZ59.17+1.33 (+2.29%) ▲|MDT79.40+1.17 (+1.50%) ▲|META618.43+55.14 (+9.79%) ▲|MMM161.68-0.23 (-0.14%) ▼|MO71.96+0.01 (+0.01%) ▲|MRK126.59-1.91 (-1.49%) ▼|MS211.51+2.47 (+1.18%) ▲|MSFT384.67+11.65 (+3.12%) ▲|MU1,053.73-100.57 (-8.71%) ▼|NEE86.95-0.82 (-0.93%) ▼|NFLX73.39+1.99 (+2.78%) ▲|NKE43.06+2.01 (+4.90%) ▲|NOW105.65+6.37 (+6.42%) ▲|NVDA196.89-3.20 (-1.60%) ▼|ORCL145.11-1.44 (-0.98%) ▼|PEP140.05+4.65 (+3.43%) ▲|PFE23.94-0.15 (-0.60%) ▼|PG146.37-0.27 (-0.18%) ▼|PLTR127.19+10.52 (+9.02%) ▲|PM178.43-2.48 (-1.37%) ▼|QCOM185.52+0.73 (+0.39%) ▲|RTX191.39+1.66 (+0.87%) ▲|SBUX101.57-0.63 (-0.61%) ▼|SCHW94.40+2.13 (+2.31%) ▲|SO95.79+0.08 (+0.08%) ▲|SPG221.82-1.84 (-0.82%) ▼|T20.64-0.06 (-0.29%) ▼|TMO520.60+19.24 (+3.84%) ▲|TMUS172.53+4.80 (+2.86%) ▲|TSLA429.34+8.74 (+2.08%) ▲|TXN299.13+1.06 (+0.36%) ▲|UBER73.35+1.19 (+1.65%) ▲|UNH421.65+6.02 (+1.45%) ▲|UNP276.15+4.15 (+1.53%) ▲|UPS109.83+2.33 (+2.17%) ▲|USB61.98+1.58 (+2.62%) ▲|V352.39+9.30 (+2.71%) ▲|VZ42.08-0.27 (-0.63%) ▼|WFC85.52+2.88 (+3.49%) ▲|WMT108.05-5.21 (-4.60%) ▼|XOM136.85+0.13 (+0.10%) ▲|
29 C
New York
Wednesday, July 1, 2026

Tag: patients

newssourceFORcompanyinformationcontent1releasesmarket

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

STATEMENT – CMA reflects on National Indigenous Peoples Day

OTTAWA, ON, June 21, 2025 /CNW/ - On this National Indigenous Peoples Day, the Canadian Medical Association (CMA) reflects on the rich history, strength...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

ICPO Foundation co-founded the RLT Angels Association with the aim of growing access to Radiotheranostics to one million patients

Further founding members include the European Association of Nuclear Medicine (EANM), GE HealthCare, Novartis, and RayzeBio, a Bristol Myers Squibb company.

ICPO Foundation ist Co-Founder der RLT Angels Association mit dem Ziel, den Zugang zur Radiotheranostik für eine Million PatientInnen auszubauen

Weitere Gründungsmitglieder sind die European Association of Nuclear Medicine (EANM), GE HealthCare, Novartis und RayzeBio, ein Unternehmen von Bristol Myers Squibb.

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Insurers Suddenly Discover Compassion—Expect a Fine Print Frenzy

As if the insurance industry needed another reminder that it's universally adored, the titans of health coverage are slinking back from their beloved pastime...

Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more...

Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA

Embrace Active Site Care Patch Becomes First Medical Device Clinically Proven to Significantly Improve Lipohypertrophy (LH) in Insulin-Using Diabetes Patients

Findings from 16-week trial of novel compression patch will be shared for the first time at the 85th Scientific Sessions of the American Diabetes...

Stem Cell-Derived Islet Therapies Shown to Reduce the Need for Injectable Insulin

Breakthrough Studies Demonstrate Stem Cell-Based Technologies as a Potential Alternative Treatment for Type 1 Diabetes CHICAGO, June 20, 2025 /PRNewswire/ -- Findings from two studies...

Novel Artificial Intelligence Models Detect Type 1 Diabetes Risk Before Clinical Onset

New Studies Highlight Machine Learning as Potential Early Risk Detection Strategy CHICAGO, June 20, 2025 /PRNewswire/ -- Developments from two studies highlighting the potential for machine...

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin...

SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, being held from June 20-23 in Chicago, IL.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatients

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers